Predictability


Fluofarma High Content Screening technology enables large-scale analysis of compounds in their real cellular environment. Thus, in contrast to standard drug discovery methods, Fluofarma's HCS technology is both powerful and highly predictive.

Our technology enables:
Functional measuring: Assessment of molecular events in living cells
Multiplexing analysis: Measure of up to 5 parameters simultaneously in single cells


Fluofarma's proprietary technology affords a highly predictive method for identifying, selecting, characterizing and understanding any kinds of compounds and its effects.  

Breaking news

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal Cell Research.

    Read more [+]

  • Publication

    Fluofarma cited in a Biocompare featured article “Flow Cytometry Gets a Makeover”

    Read more [+]

  • Press Release

    Roche adopts Fluofarma’s high-content screening platform.

    Read more [+]

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal "Analytical Chemistry".

    Read more [+]

Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into a multi-year agreement with Roche.
Read More



ALL NEWS